RevvoMed is a Stockholm-based drug discovery company, founded in 2025, that develops precision cancer medicines by targeting membrane proteins. Its proprietary platform maps cell-surface proteins that conventional approaches struggle to reach, aiming for more precise drug targets and fewer side effects than current cancer treatments. The science builds on membrane-protein research by co-founder Robin Löving at Karolinska Institutet, and the company expects to partner with pharmaceutical companies to move its candidates toward the market.
1
Round
1
Industry
5
Tags
Oct 31, 2026
Latest raise
Funding activity · 1 round
Oct 31, 2026
SEK 7M
Seed
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
